Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Genprex, Inc. - Common Stock (NQ:GNPX)

0.2430 +0.0151 (+6.63%)
Streaming Delayed Price Updated: 3:12 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Genprex, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Planned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)
Via Get News
Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer and Diabetes: Genprex, Inc. (Nasdaq: GNPX)
Via Get News
Topics Intellectual Property
Clinical Trials Commenced for Promising Acclaim-3 Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer: Genprex, Inc. (NASDAQ: GNPX)
Via Get News
New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)
Via Get News
BioMedNewsBreaks — Genprex Inc. (NASDAQ: GNPX) Announces Participation at Upcoming Investor, Industry Events
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPRL2 Gene Therapy
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
Via Investor Brand Network
TechMediaBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering
Via Investor Brand Network
TinyGemsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Adds Korean Patent for Leading Drug Candidate to Growing International Patent Portfolio
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Preclinical Data to be Presented at Upcoming AACR Annual Meeting
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion of Nonclinical Programs into New Therapeutic Indications
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO & Investor Conference
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrolls, Doses First Patient
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Presented Data at Two October Events Focused on Lung Cancer
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023
Via Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Schedules, Hosts Virtual Key Opinion Leader Event
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lung Cancer Treatment at 2023 AACR-NIH-EORTC Conference
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
From Genprex, Inc.
Via GlobeNewswire
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio for Its Diabetes Gene Therapy Program
Via Investor Brand Network
Topics Intellectual Property
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
Via FinancialNewsMedia
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations
Via Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conference
Via Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’
Via Investor Brand Network
Topics Intellectual Property
Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.